Document is current
Any future updates will be listed below
-
Authors
Pedrazzoli, Eleonora https://orcid.org/0000-0002-8420-2587
Demozzi, Michele
Visentin, Elisabetta https://orcid.org/0000-0001-6586-4123
Ciciani, Matteo https://orcid.org/0000-0003-2045-5435
Bonuzzi, Ilaria https://orcid.org/0000-0003-3179-474X
Pezzè, Laura https://orcid.org/0000-0001-8924-0083
Lucchetta, Lorenzo
Maule, Giulia https://orcid.org/0000-0002-7770-5688
Amistadi, Simone https://orcid.org/0000-0002-1140-9165
Esposito, Federica https://orcid.org/0000-0002-8521-4627
Lupo, Mariangela
Miccio, Annarita https://orcid.org/0000-0002-3409-9665
Auricchio, Alberto https://orcid.org/0000-0002-0832-2472
Casini, Antonio https://orcid.org/0000-0001-7709-4955
Segata, Nicola https://orcid.org/0000-0002-1583-5794
Cereseto, Anna https://orcid.org/0000-0003-4453-2597
- License Information
-
More Information
Article History
Received: 5 January 2024
Accepted: 11 April 2024
First Online: 24 April 2024
Competing interests
: The authors declare competing financial interests: A.Ce. is a co-founder and holds stocks of Alia Therapeutics, a genome editing company. A.Ca. is a co-founder, holds stocks and is currently an employee of Alia Therapeutics. L.P. is an employee of Alia Therapeutics. M.C. and N.S. are consultants of Alia Therapeutics. AA is co-founder and shareholder of InnovaVector. Pending patent applications (WO2023118349 and WO2024056880, claiming priority to USPTO applications) covering nucleases presented in this work have been filed by Alia Therapeutics. The remaining authors declare no competing interests.
